LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy

Breast cancer, with around 2 million new cases in 2019, is the second most common cancer worldwide and leading cause of death among females. The aim this work to prepare a targeting nanoparticle through conjugation LinTT1 peptide, specific molecule p32 protein overexpressed by breast associated cells, on liposomes’ surface. This approach increases cytotoxic effects doxorubicin (DOX) sorafenib (SRF) co-loaded therapeutic liposomes both 2D 3D cellular models. liposome functionalization leads higher interaction spheroids than bare ones. Moreover, studies between LinTT1-functionalized M2 primary human macrophages show an internalization 50% total nanovesicles that interact these while other results only cell finding suggests possibility use amount enrich hypoxic tumor area, exploiting ability accumulate central core mass. These promising highlight potential DOX SRF as nanomedicines for treatment especially triple negative cells.